Abstract | PURPOSE: MATERIALS AND METHODS: The study was approved by the local ethics committee, and patient informed consent was obtained. Patients with peripheral arterial occlusions less than 60 days old (n=120) were enrolled in the study: 50 patients (32 men, 18 women; mean age, 67 years; range, 23-88 years) received reteplase plus abciximab and 70 patients (36 men, 34 women; mean age, 68 years; range, 28-88 years) received urokinase plus abciximab. Study end points were the rate of major complications at 30 days, therapeutic success, and survival without open surgery or major amputation at follow-up. Fisher exact test was used to compare treatment groups with respect to dichotomous variables, and the event-free-survival probabilities were calculated with the Kaplan-Meier method. For the comparison of the lengths of occlusions among the groups, a two-sample t test was used. RESULTS: Therapeutic success (P=.7) did not differ between the groups, whereas the time required for thrombolysis was lower in the urokinase-plus- abciximab group (P=.001). Patients who received reteplase plus abciximab tended to develop more minor complications (mainly bleeding events) (P<.001). During long-term follow-up (2-4 years), no group differences were observed. The reocclusion rate was 48% (22 of 46) in the reteplase-plus- abciximab group and 45% (29 of 64) in the urokinase-plus- abciximab group. Only two of 120 major amputations were counted in the follow-up period. CONCLUSION: The proposed regimen resulted in only a limited number of major complications, and the low amputation rate in both groups may be attributed to abciximab.
|
Authors | Gunnar Tepe, Claudius Hopfenzitz, Klaus Dietz, Jakub Wiskirchen, Stephan Heller, Kenneth Ouriel, Gerhard Ziemer, Claus D Claussen, Stephan H Duda |
Journal | Radiology
(Radiology)
Vol. 239
Issue 3
Pg. 892-900
(Jun 2006)
ISSN: 0033-8419 [Print] United States |
PMID | 16641342
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright (c) RSNA, 2006. |
Chemical References |
- Antibodies, Monoclonal
- Drug Combinations
- Fibrinolytic Agents
- Immunoglobulin Fab Fragments
- Platelet Glycoprotein GPIIb-IIIa Complex
- Recombinant Proteins
- reteplase
- Tissue Plasminogen Activator
- Urokinase-Type Plasminogen Activator
- Abciximab
|
Topics |
- Abciximab
- Adult
- Aged
- Aged, 80 and over
- Amputation, Surgical
- Antibodies, Monoclonal
(administration & dosage, adverse effects, therapeutic use)
- Arterial Occlusive Diseases
(drug therapy)
- Drug Combinations
- Female
- Fibrinolytic Agents
(administration & dosage, adverse effects, therapeutic use)
- Follow-Up Studies
- Hemorrhage
(chemically induced)
- Humans
- Immunoglobulin Fab Fragments
(administration & dosage, adverse effects, therapeutic use)
- Longitudinal Studies
- Male
- Middle Aged
- Peripheral Vascular Diseases
(drug therapy)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Prospective Studies
- Recombinant Proteins
(administration & dosage, adverse effects, therapeutic use)
- Recurrence
- Safety
- Thrombolytic Therapy
(adverse effects)
- Time Factors
- Tissue Plasminogen Activator
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
- Urokinase-Type Plasminogen Activator
(administration & dosage, adverse effects, therapeutic use)
|